Literature DB >> 61963

Inhibition of activated factor XII by antithrombin-heparin cofactor.

N Stead, A P Kaplan, R D Rosenberg.   

Abstract

The activation of Factor XII occurs via fragmentation of this zymogen into a diverse spectrum of enzymatically potent molecular species. To study the interaction of antithrombin-heparin cofactor and heparin with activated Factor XII, we have employed two forms of this enzyme with widely differing physical characteristics and biologic potencies. Antithrombin-heparin cofactor was found to be a progressive, time-dependent inhibitor of both forms. The addition of heparin dramatically accelerated the rates of these interactions. Furthermore, sodium dodecyl sulfate gel electrophoresis of reduced proteins has indicated that antithrombin-heparin cofactor functions by forming an undissociable complex with either species of the enzyme. This complex represents a 1:1 stoichiometric combination of activated Factor XII and inhibitor. In the presence of heparin, both species undergo virtually instantaneous complex formation with antithrombin-heparin cofactor without exhibiting alterations in dissociability or stoichiometry.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 61963

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

Review 1.  FXII.

Authors:  G Fuhrer; M J Gallimore; W Heller; H E Hoffmeister
Journal:  Blut       Date:  1990-11

2.  Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein.

Authors:  H L Meier; J V Pierce; R W Colman; A P Kaplan
Journal:  J Clin Invest       Date:  1977-07       Impact factor: 14.808

Review 3.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 4.  Postoperative changes in hemostasis analyzed by the serial determination of fibrinopeptides and D-dimer.

Authors:  J Kang; J Kambayashi; M Sakon; T Tsujinaka; T Mori
Journal:  Jpn J Surg       Date:  1989-05

5.  Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients.

Authors:  B L Zuraw; J G Curd
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

6.  The irradiation of Babesia bovis. 1. The difference in pathogenicity between irradiated and non-irradiated populations.

Authors:  I G Wright; B V Goodger; D F Mahoney
Journal:  Z Parasitenkd       Date:  1980

Review 7.  Natural anticoagulant mechanisms.

Authors:  R D Rosenberg; J S Rosenberg
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

8.  Cloning and expression of the cDNA for human antithrombin III.

Authors:  S C Bock; K L Wion; G A Vehar; R M Lawn
Journal:  Nucleic Acids Res       Date:  1982-12-20       Impact factor: 16.971

9.  Expression of functionally active human antithrombin III.

Authors:  A W Stephens; A Siddiqui; C H Hirs
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

10.  Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.

Authors:  A de Agostini; H R Lijnen; R A Pixley; R W Colman; M Schapira
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.